Switzerland: Healthcare

Switzerland's medical device regulatory framework in 2026 presents a complex landscape shaped by alignment with EU standards, post-Brexit market access challenges, and evolving requirements for product registration and transparency. How do manufacturers navigate classification systems, conformity assessments, and post-market surveillance obligations while managing the implications of Switzerland's third-country status for medical devices in the European Union?

In its judgment of 22 January 2026 (C-9459/2025), the Swiss Federal Administrative Court (FAC) clarified a fundamental procedural issue...

On January 1, 2020, the revised Swiss integrity, transparency and discounts (ITD) regime in the therapeutic products sector came into force.